Diluted patient serum is added to wells coated with purified antigen. IgG specific antibody, if present, binds to the antigen. All unbound materials are washed away and the enzyme conjugate is added to bind to the antibody-antigen complex, if present. Excess enzyme conjugate is washed off and substrate is added. The plate is incubated to allow the hydrolysis of the substrate by the enzyme. The intensity of the color generated is proportional to the amount of IgG specific antibody in the sample.
Proben
Serum
Analytische Methode
Qualitative
Plattentyp
Pre-coated
Beschränkungen
Nur für Forschungszwecke einsetzbar
Lagerung
4 °C
Target
Scl-70
Hintergrund
Systemic autoimmune disease is characterized by the presence of circulating auto-antibodies directed to a wide variety of cellular antigens.Systemic lupus erythematosis (SLE), commonly referred to as Lupus is the best known of these diseases. Other possible connective tissue diseases include mixed connective tissue disease (MCTD), Sjogren syndrome, sclerodema, and polymyositisdermatomyositis.The majority can be diagnosed by clinical presentation and their antibody profiles to the various antigens involved, which include dsDNA, SM, RNP, SSA, SSB Scl-70, Jo1 and Histones. Therefore, immunoassays for autoantibodies are useful for diagnostic and prognostic evaluations of autoimmune disease. Scl-70 IgG antibodies react with human topoisomerase I of 100 kd molecular weight as well as its 70 kd fragment. Scl-70 antibodies are present in 20-40% of diffuse scleroderma patients and in about 20% of patients with limited scleroderma.Scl-70 antibodies are sometimes reported in classical SLE without features of scleroderma, which may explain the unexpected co-existence of marker autoantibodies for SLE and scleroderma. Some patients with silica-associated systemic sclerosis (SSc) have Scl-70 antibodies.